Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Investor Day (June 2025)
14 slides from Fresenius Medical Care's investor day presentation, Jun 17, 2025
Slide 1: Deep-dive breakout session: Care Enablement
Q4 2024 Conference Call Deep-dive breakout session Care Enablement Dr. Katarzyna Mazur-Hofsäß, CEO Care Enablement Joseph Turk, Global Head of Home and Critical Care Therapies, Head of U.S. Commercial Operations London | June 17, 2025
Slide 2: Safe harbor statement
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conve
Slide 3: Care Enablement | Accelerating profitable growth to 2030
Reignite Care Enablement | Accelerating profitable growth to 2030 Q4 2024 Value Conference Call Creation Path to mid-teens operating margin aspiration Mid-teens 6.0% Pricing excellence and market share expansion U.S. HVHDF (5008X) rollout Focused R&D program | Innovation FME25+ Operational and Proce
Slide 4: Innovation and new technology have consistently boosted our margins and consumable attachment rates
Reignite Innovation and new technology have consistently boosted our Q4 2024 Growth & Conference Call margins and consumable attachment rates Innovation A comparison by year of introduction with U.S. as an outlier Technology evolution In-center model overview Year of initial market launch installed
Slide 5: Innovation delivers value by enabling share gains and growing profit pool
Reignite Innovation delivers value Q4 2024 Growth & by enabling share gains and growing profit pool Conference Call Innovation Medical outcomes Suppliers Competitors Operational efficiency Patient Innovation experience profit pool Cost reduction Payors Customers Sustainability Capital Markets Day Ju
Slide 6: Unlocking the HVHDF potential in the U.S. enabled by 5008X
Reignite Unlocking the HVHDF potential in the U.S. Q4 2024 Growth & Conference Call enabled by 5008X Innovation 23% reduction in mortality Significant improvement rates in patient quality of life Proven reliability and long- Simplified workflows for term durability platform clinical staff Enhanced p
Slide 7: Innovation delivers value
Reignite Innovation delivers value Q4 2024 Growth & by enabling share gains and growing profit pool Conference Call Innovation Showing the value of innovation as an investment in our strategy Medical outcomes Product innovations Digital experience innovations Operational efficiency Patient experienc
Slide 8: Examples of our current, already in-market innovation
Reignite Examples of our current, already in-market innovation Q4 2024 Growth & Conference Call Innovation The Helixone® hydro membrane forms a hydrolayer on the inner membrane surface for reduced protein Medical adsorption resulting in a membrane with low immune response and high selective permeabi
Slide 9: Examples of our current, already in-market innovation
Reignite Examples of our current, already in-market innovation Q4 2024 Growth & Conference Call Innovation We innovate our dialyzers to increase medical efficacy, Medical reduce cost and improve sustainability outcomes Operational Optiflux FX CorAL Thunderbird efficiency Launched First launched Plan
Slide 10: Examples of our current, already in-market innovation
Reignite Examples of our current, already in-market innovation Q4 2024 Growth & Conference Call Innovation CAREset introduced a much simpler, efficient and user-friendly bloodline technology that improves Medical patient outcomes, reduces therapy complexity and optimizes resource utilization in dial
Slide 11: Examples of our current, already in-market innovation
Reignite Examples of our current, already in-market innovation Q4 2024 Growth & Conference Call Innovation NxStage home hemodialysis with “GuideMe Software” supports patients in applying the therapy Medical in the correct way, empowering the patient and increasing patient safety outcomes Operational
Slide 12: Examples of our current, already in-market innovation
Reignite Examples of our current, already in-market innovation Q4 2024 Growth & Conference Call Innovation Using Augmented Reality (AR) for re-training of clinicians on the multiFiltratePRO: AR training offers immersive, Medical on-demand learning for AKI (Acute Kidney Injury), addressing nursing sh
Slide 13: We lead kidney care through exceptional patient care and innovation
Q4 2024 Conference Call We lead kidney care through exceptional patient care and innovation
Slide 14: Contacts
Contacts Q4 2024 Conference Call Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v. d. H. Germany Dr. Dominik Heger Ilia Kuerten Alicia Cahill ir@FreseniusMedicalCare.com Head of Investor Relations Vice President Senior Director and Investor Relations Investor Rel